Israel L, Rodary C
J Int Med Res. 1978;6(3):235-40. doi: 10.1177/030006057800600311.
Two controlled double-blind studies were carried out successively on a cancerous out-patient population receiving multiple combination chemotherapy at successive treatment courses to show the anti-emetic efficiency of metopimazine compared to a placebo. The patient was taken as his own control and the treatment order was randomly selected. The first trial--consisting of sixty-seven patients, showed a weak statistically significant difference (0.05 less than p less than 0.10) between metopimazine at doses of 30 mg/day or 15 mg/day and a placebo. The second trial--comparing a higher dose of metopimazine (45 mg/day) among one hundred and sixteen patients, showed a highly statistically significant therapeutic advantage over a placebo (0.001 less than p less than 0.01).
两项对照双盲研究先后在接受多药联合化疗的癌症门诊患者连续治疗疗程中进行，以显示甲哌氯丙嗪相对于安慰剂的止吐效果。患者以自身作为对照，治疗顺序随机选择。第一项试验——由67名患者组成，显示30毫克/天或15毫克/天剂量的甲哌氯丙嗪与安慰剂之间存在统计学上的微弱显著差异（0.05＜p＜0.10）。第二项试验——在116名患者中比较更高剂量的甲哌氯丙嗪（45毫克/天），显示出相对于安慰剂具有高度统计学意义的治疗优势（0.001＜p＜0.01）。
